Which prostate cancer drug is kinder to your brain?

NCT ID NCT04335682

First seen Nov 05, 2025 · Last updated May 14, 2026 · Updated 27 times

Summary

This study looks at how two different prostate cancer medications, darolutamide and enzalutamide, affect thinking skills like memory and attention. About 111 men with advanced prostate cancer will take one of the two drugs and complete computer-based brain tests over time. The goal is to see which drug causes fewer mental side effects, helping doctors choose the best treatment for each patient.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

  • Froedtert and the Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois, 60611, United States

  • University of California - San Francisco at Mount Zion

    San Francisco, California, 94115, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Kansas Cancer Center

    Fairway, Kansas, 66205, United States

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States

  • University of Oklahoma

    Oklahoma City, Oklahoma, 73104, United States

Conditions

Explore the condition pages connected to this study.